CML Treatment Enters the Digital Era: Big Data-Driven Platform Launches with IPO Filing

Guangzhou, November 8, 2019 /PRNewswire/ -- Today, the "CML Treatment Outcome Index Project," hosted by the Chinese Anti-Cancer Association (CACA) and supported by Novartis Oncology (China), was officially launched. With the advancement of modern medicine and the continuous update and market approval of therapeutic drugs, significant breakthroughs have been achieved in the treatment of chronic myeloid leukemia (hereinafter referred to as CML). However, as the population of CML patients continues to grow, disease management faces increasing clinical pressure and economic burden. This project aims to create clinical decision-making models through scientific and systematic data processing and analysis, thereby helping clinicians optimize treatment decisions and management strategies, facilitating the optimal allocation of medical resources, and ultimately alleviating the patient burden in a reasonable manner.

CML Treatment Outcome Index Project Launched, Facilitating Standardization and Optimized Decision-Making

Tyrosine kinase inhibitors (TKIs) are widely used as first-line agents for the treatment of chronic myeloid leukemia (CML) and demonstrate significant efficacy; currently, the long-term survival of CML patients approaches that of the general population. However, under the traditional model of CML diagnosis and management, challenges persist in areas such as treatment follow-up, patient management, and financial burden.

Chronic Myeloid Leukemia (CML) Treatment Outcome Index ProjectThe CML Treatment Outcome Index Project will leverage real-world data collection from clinical practice, employing standardized, feedback-driven model analysis to continuously optimize disease diagnosis and treatment pathways and regimens, thereby establishing a quantitative and implementable clinical management framework. Meanwhile, the project will model, summarize, and disseminate clinical treatment expertise from top-tier medical centers, with the aim of comprehensively enhancing the clinical practice capabilities of primary care physicians, improving the overall quality and balanced development of CML treatment nationwide. This initiative seeks to help CML patients achieve optimal treatment outcomes, while optimizing the allocation of healthcare resources and reasonably reducing the medical burden.

Yan Zhao, Director of the Department for Continuing Education and Scientific & Technological Services at the China Anti-Cancer Association, stated: “Promoting the application of health and medical big data is a key component of the ‘Healthy China 2030’ Planning Outline. Comprehensively deepening the application of health and medical big data in areas such as industry governance, clinical practice and scientific research, public health, and education and training will be the focal point of work over the next decade. The Chronic Myeloid Leukemia (CML) Treatment Outcome Index project establishes a simple and intuitive index, based on modeling, to assess the current status of CML treatment among the Chinese population. This initiative aids in establishing standards, optimizing decision-making, improving efficiency, and enhancing resource allocation.”

Professor Wang Jianxiang, Chairman of the Hematology Branch of the Chinese Medical Association, stated: “Current treatment for chronic myeloid leukemia (CML) lacks appropriate models for evaluating clinical financial burden and methods for assessing drug cost-effectiveness. Meanwhile, the dual phenomena of wasted medical resource investment and shortage of medical resources persist, leading to polarization in clinical experience and failing to meet the needs of the growing patient population. The CML Treatment Outcome Index project facilitates the summary and dissemination of treatment expertise through continuous big data collection and accumulation, thereby assisting clinicians in improving disease management.””

This itemThe project is scheduled to launch pilot initiatives in selected hospitals from 2019 to 2020, collecting retrospective data on the diagnosis, treatment, and follow-up of chronic myeloid leukemia (CML) to establish models and summarize CML diagnostic and therapeutic pathways, thereby accumulating experience for subsequent nationwide promotion.

"Under the support of best clinical practice models, patients are expected to achieve optimal treatment outcomes."

“Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukemia in China (2016 Edition)” state that “epidemiological surveys in several regions of China have shown an annual incidence of CML of 0.39–0.55 per 100,000 population. Compared with Western countries, CML patients in China are younger, with a median age at diagnosis of 45–50 years.”

CML Treatment Outcome Index ProjectThe CML Treatment Outcome Index Project comprises three major modules: the Clinical Diagnosis and Treatment Module, the Patient Management Module, and the Medical Cost Module. Through big data analysis, a final data model is established. Subsequently, based on relevant data indicators during the treatment process, probable outcomes are projected. By reviewing treatment protocols from top domestic experts and conducting comparative analyses of key indicators, the reasons for failing to achieve treatment goals can be identified. This enables adjustments to treatment regimens or improvements in disease management strategies, ultimately approaching optimal treatment outcomes.

By leveraging the standardized, feedback-driven diagnosis and treatment model of the CML Treatment Outcome Index project, a multi-stakeholder win-win scenario will be established. Public health administrators can gain insight into real-world clinical needs of physicians and patients, optimize the allocation and utilization efficiency of healthcare resources, and support the formulation and implementation of innovative healthcare policies. Clinical experts can further advance academic development in the field of chronic myeloid leukemia (CML) and leverage the practical guidance role of innovative clinical decision support systems. The clinical practice capabilities of primary care physicians are expected to improve comprehensively, fostering collaboration and communication between tertiary and primary hospitals, thereby enhancing the overall level and balanced development of CML treatment. Supported by collective best clinical practice models among physicians, CML patients will achieve optimal individual treatment outcomes. Novartis China will continue to uphold its patient-centric philosophy and strive relentlessly to realize the best possible treatment outcomes for CML patients.

The initial phase of the project will establish more optimized clinical diagnosis and treatment pathways based on historical data combined with expert experience, while future efforts will continue to conduct additional prospective real-world research studies.

Professor Wang Jianxiang recommends integrating evidence-based guidelines with real-world evidence (RWE) treatment outcome models to determine the optimal clinical decision pathway tailored to individual patients, while establishing best practices for real-world clinical care to enhance the overall effectiveness of healthcare resource management, thereby working together to achieve the best possible treatment outcomes for patients with chronic myeloid leukemia (CML).

Disclaimer: This material is intended to provide relevant knowledge about disease areas and enhance disease awareness, and is not for advertising purposes. The information contained herein is for reference only; please follow the advice or guidance of physicians or other qualified healthcare professionals.